Cargando…

Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection

BACKGROUND: This study aimed to consider the main risk factors related to adverse clinical outcomes in MS patients with COVID-19. METHODS: Using the electronic health records systems, this is a cross-sectional study of two years of hospital admissions in terms of COVID-19 in Iran from March 2019 to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maghbooli, Zhila, Hosseinpour, Hesham, Fattahi, Mohammad Reza, Varzandi, Tarlan, Hamtaeigashi, Sara, Mohammad-nabi, Sara, Aghababaei, Yasaman, Sahraian, Mohammad Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306262/ https://www.ncbi.nlm.nih.gov/pubmed/35933755 http://dx.doi.org/10.1016/j.msard.2022.104067

Ejemplares similares

Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients
por: Maghbooli, Zhila, et al.
Publicado: (2023)

Reduction in circulating vitamin D binding protein in patients with multiple sclerosis
por: Maghbooli, Zhila, et al.
Publicado: (2021)

The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder
por: Maghbooli, Zhila, et al.
Publicado: (2021)

Multiple sclerosis and human leukocyte antigen genotypes: Focus on the Middle East and North Africa region
por: Maghbooli, Zhila, et al.
Publicado: (2020)

Treatment With 25-Hydroxyvitamin D(3) (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
por: Maghbooli, Zhila, et al.
Publicado: (2021)

Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease
por: Emamgholipour, Solaleh, et al.
Publicado: (2013)

Correction: Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease
por: Emamgholipour, Solaleh, et al.
Publicado: (2013)

Correction: Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease
por: Emamgholipour, Solaleh, et al.
Publicado: (2014)

Bone mineral density and muscle mass in adults with developmental skeletal discrepancies
por: Sharifi, Reza, et al.
Publicado: (2022)

Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis
por: Valizadeh, Amir, et al.
Publicado: (2022)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2018)

SCCmec Genotypes of Methicillin-Resistant Staphylococcus aureus in Nasal Carriage of Multiple Sclerosis Patients in Iran
por: JAMSHIDI, Yasaman, et al.
Publicado: (2019)

Translation and validation of the Persian version of Godin Leisure-Time Exercise Questionnaire in patients with multiple sclerosis
por: Fattahi, Mohammad-Reza, et al.
Publicado: (2021)

Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta‐analysis
por: Valizadeh, Amir, et al.
Publicado: (2021)

Assessment of COVID-19 vaccine attitude in people with multiple sclerosis, its correlation with demographic factors, and fear of coronavirus: A cross-sectional survey
por: Fattahi, Mohammad Reza, et al.
Publicado: (2022)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
por: Maghbooli, Zhila, et al.
Publicado: (2020)

Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports
por: Rastkar, Mohsen, et al.
Publicado: (2023)

The Factors Associated With Olfactory Dysfunction in Patients with Multiple Sclerosis
por: Almasi, Mostafa, et al.
Publicado: (2021)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

Blood Concentrations of Cadmium and Lead in Multiple Sclerosis Patients from Iran
por: Aliomrani, Mehdi, et al.
Publicado: (2016)

Effect of an educational intervention based on the theory of planned behavior on improving medication adherence in patients with multiple sclerosis treated with injectable disease-modifying drugs: randomized controlled trial
por: Hamtaeigashti, Sara, et al.
Publicado: (2023)

Prevalence of Multiple Sclerosis (MS) in Zanjan Province of Iran
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

The prevalence of multiple sclerosis in Tehran, Iran, in 2020
por: Eskandarieh, Sharareh, et al.
Publicado: (2023)

Vitamin D and multiple sclerosis
por: Harandi, Asghar Amini, et al.
Publicado: (2014)

Association Study of Estrogen Receptor Alpha Gene Polymorphisms with Spontaneous Abortion: Is This a Possible Reason for Unexplained Spontaneous Abortion?
por: Anousha, Negin, et al.
Publicado: (2013)

Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva(®)) in Patients with Multiple Sclerosis: An Observational Retrospective Study
por: Abolfazli, Roya, et al.
Publicado: (2023)

Is it time to revise the classification of geographical distribution of multiple sclerosis?
por: Sahraian, Mohammad Ali, et al.
Publicado: (2012)

Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran
por: Omrani, Mohammad Amin, et al.
Publicado: (2023)

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020)

Effects of Eight-week Resistance Training Program in Men With Multiple Sclerosis
por: Moradi, Mahbubeh, et al.
Publicado: (2015)

Clinical and demographic factors affecting disease severity in patients with multiple sclerosis
por: Baghizadeh, Somayeh, et al.
Publicado: (2013)

Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020)

Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran
por: ESKANDARIEH, Sharareh, et al.
Publicado: (2017)

Burden of multiple sclerosis in Iran from 1990 to 2017
por: Fattahi, Nima, et al.
Publicado: (2021)

Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis
por: Azimi, Amirreza, et al.
Publicado: (2019)

Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis
por: Baghizadeh, Somayyeh, et al.
Publicado: (2016)

Evaluation of the Opinion of Patients With Multiple Sclerosis on the Outcomes of Catching COVID-19 and Its Effects on the MS Symptoms
por: Rezaeimanesh, Nasim, et al.
Publicado: (2020)

Determinants of sexual dysfunction in women with multiple sclerosis
por: Mohammadi, Khadijeh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ne6v4pi2fa7pgqfevmu5011imm